Press release
Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akero, Allergan, Amgen, ARTham, Ascletis, Pharmaxis, Cerenis, Merck, DURECT, Enanta
"Non-Alcoholic Steatohepatitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Therapeutics Market.
The report provides a detailed description of the Non-Alcoholic Steatohepatitis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Non-Alcoholic Steatohepatitis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Non-Alcoholic Steatohepatitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Non-Alcoholic Steatohepatitis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Non-Alcoholic Steatohepatitis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Non-Alcoholic Steatohepatitis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Non-Alcoholic Steatohepatitis Therapeutics Domain @
https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Non-Alcoholic Steatohepatitis Therapeutics Analysis
Presently, there are no FDA, EMA, or PMDA (Pharmaceuticals and Medical Devices Agency) approved for the treatment of NASH, however, researchers are studying medicines that may improve these conditions. The current treatment The current front-line treatment consists of lifestyle modifications, such as diet and exercise. Additional treatment options for NASH, aside from lifestyle modifications, have included off-label use of vitamin E and anti-diabetes agents (e.g., pioglitazone and liraglutide).
Several major pharma and biotech companies are developing therapies for Nonalcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Nonalcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.
Non-Alcoholic Steatohepatitis Companies in the Therapeutics Market Include:
Akero Therapeutics, Albireo Pharma, Allergan, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, Conatus Pharmaceuticals, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Galmed, Genfit, Gilead Sciences, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, HighTide Biopharma, Ildong Pharmaceutical, InorbitTX, Intercept Pharmaceuticals, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.
Emerging and Marketed Non-Alcoholic Steatohepatitis Therapies Covered in the Report Include:
• Aramchol_005: Galmed
• Cenicriviroc: Allergan- Tobira
• EDP-305: Enanta Pharmaceuticals
• Elafibranor: Genfit
• Emricasan: Conatus Pharmaceuticals
• GS-9674: Gilead Sciences
• HTD 1801: HighTide Biopharma
• HU 6: Rivus Pharmaceuticals
• ION224: Ionis Pharmaceuticals
• MSDC-0602K: Cirius Therapeutics
• OCA: Intercept Pharmaceuticals
• Resmetirom: Madrigal Pharmaceuticals
• Selonsertib: Gilead Sciences
And many more
Get an in-depth Assessment of the Emerging Therapies and Non-Alcoholic Steatohepatitis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Non-Alcoholic Steatohepatitis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Non-Alcoholic Steatohepatitis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Steatohepatitis Current Treatment Patterns
4. Non-Alcoholic Steatohepatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Steatohepatitis Late-Stage Products (Phase-III)
7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Steatohepatitis Discontinued Products
13. Non-Alcoholic Steatohepatitis Product Profiles
14. Non-Alcoholic Steatohepatitis Companies
15. Non-Alcoholic Steatohepatitis Drugs
16. Dormant and Discontinued Products
17. Non-Alcoholic Steatohepatitis Unmet Needs
18. Non-Alcoholic Steatohepatitis Future Perspectives
19. Non-Alcoholic Steatohepatitis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Akero, Allergan, Amgen, ARTham, Ascletis, Pharmaxis, Cerenis, Merck, DURECT, Enanta here
News-ID: 3318179 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
